Sabatolimab in Combination with Hypomethylating Agents (HMAs) Was Safe in Patients (Pts) with Intermediate-, High-, or Very-High-Risk Myelodysplastic Syndrome (MDS)Guillermo Garcia-Manero,Roger M. Lyons,Savita Nandal, Mushtaq Ashraf, Ramarao Thellaboina, Julie Ruckel-Kumar,Hans D. Menssen,Amer M. ZeidanBLOOD（2023）引用 0|浏览3暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
